Tanja Charlotte Frederiksen

Tanja Charlotte Frederiksen

Auto-generated profile, based on publicly available information

Tanja Charlotte Frederiksen

Department of Cardiology Aarhus University Hospital Aarhus Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2023 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
TFTanja Charlotte Frederiksen
Tanja Charlotte Frederiksen
CDChristina C Dahm
Christina C Dahm
SPSarah R. Preis
Sarah R. Preis
HLHonghuang Lin
Honghuang Lin
LTLudovic Trinquart
Ludovic Trinquart
JKJelena Kornej
Jelena Kornej

16 August 2021 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
ACAlex Hørby Christensen
Alex Hørby Christensen
PPPyotr G Platonov
Pyotr G Platonov
HJHenrik Kjærulf Jensen
Henrik Kjærulf Jensen
MCMonica Chivulescu
Monica Chivulescu
ASAnneli Svensson
Anneli Svensson
HBHenning Bundgaard
Henning Bundgaard
Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is predominantly caused by desmosomal genetic variants, and clinical hallmarks include arrhythmias and systolic dysfunction. We aimed at studying the impact of the implicated gene(s) on the disease course. Methods: The Nordic ARVC Registry holds data on a multinational cohort of ARVC families. The effects of genotype on electrocardiographic features, imaging findings and clinical events were analysed. Results: We evaluated 419 patients (55% men), with a mean follow-up of 11.2±7.4 years. A pathogenic desmosomal variant was identified in 62% of the 230 families: PKP2 in 41%, DSG2 in 13%, DSP in 7% and DSC2 in 3%. Reduced left ventricular ejection fraction (LVEF) ≤45% on cardiac MRI was more frequent among patients with DSC2/DSG2/DSP than PKP2 ARVC (27% vs 4%, p<0.01). In contrast, in Cox regression modelling of patients with definite ARVC, we found a higher risk of arrhythmias among PKP2 than DSC2/DSG2/DSP carriers: HR 0.25 (0.10–0.68, p<0.01) for atrial fibrillation/flutter, HR 0.67 (0.44–1.0, p=0.06) for ventricular arrhythmias and HR 0.63 (0.42–0.95, p<0.05) for any arrhythmia. Gene-negative patients had an intermediate risk (16%) of LVEF ≤45% and a risk of the combined arrhythmic endpoint comparable with DSC2/DSG2/DSP carriers. Male sex was a risk factor for both arrhythmias and reduced LVEF across all genotype groups (p<0.01). Conclusion: In this large cohort of ARVC families with long-term follow-up, we found PKP2 genotype to be more arrhythmic than DSC2/DSG2/DSP or gene-negative carrier status, whereas reduced LVEF was mostly seen among DSC2/DSG2/DSP carriers. Male sex was associated with a more severe phenotype.

4 June 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
TFTanja Charlotte Frederiksen
Tanja Charlotte Frederiksen
Emelia J. BenjaminEmelia J. Benjamin
Emelia J. Benjamin
LTLudovic Trinquart
Ludovic Trinquart
HLHonghuang Lin
Honghuang Lin
CDChristina C Dahm
Christina C Dahm
JKJelena Kornej
Jelena Kornej
Background: Individuals with both atrial fibrillation (AF) and myocardial infarction (MI) have higher mortality compared with individuals with only 1 condition. Whether mortality differs according to the temporal order of AF and MI is unclear. Methods and Results: We included participants from the FHS (Framingham Heart Study) from 1960 and onwards. We assessed the hazard ratio (HR) of new‐onset AF and MI, and mortality according to MI and AF status (prevalent and interim) using multivariable‐adjusted Cox proportional hazards models. Interim diseases were modeled as time‐varying variables. For the analysis of new‐onset AF, 10 923 participants (55% women; mean±SD age, 54±8 years) were included. For new‐onset MI, 10 804 participants (55% women; mean±SD age, 54±8 years) were included. Compared with no MI, the hazard of new‐onset AF was higher in participants with prevalent (HR, 1.60 [95% CI, 1.32–1.94]) and interim MI (HR, 3.96 [95% CI, 3.18–4.91]). Both ST‐segment–elevation MI and non–ST‐segment–elevation MI were associated with new‐onset AF. Interim AF, not prevalent AF, was associated with higher hazard rate of new‐onset MI (HR, 2.21 [95% CI, 1.67–2.92]). Interim AF was associated with both ST‐segment–elevation MI and non–ST‐segment–elevation MI. Mortality was significantly greater among participants with AF and MI compared with participants with 1 of the 2, regardless of temporal order. Conclusions: We report a bidirectional association between AF and MI, which was observed for both non–ST‐segment–elevation MI and ST‐segment–elevation MI. Participants with both AF and MI had considerably higher mortality compared with participants with only 1 of the 2 conditions, regardless of order.

1 August 2018 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
TFTanja Charlotte Frederiksen
Tanja Charlotte Frederiksen
MCMorten Krogh Christiansen
Morten Krogh Christiansen
PØPernille Charmoth Østergaard
Pernille Charmoth Østergaard
PTPer Hove Thomsen
Per Hove Thomsen
CGClaus Graff
Claus Graff
HJHenrik Kjærulf Jensen
Henrik Kjærulf Jensen
Background: The literature contains several cases of anorexia nervosa (AN) patients with prolonged QTc interval. However, the risk of prolonged QTc interval is controversial and the risk of cardiac events in AN patients has yet to be investigated. Methods: We estimated the difference in mean QTc interval and relative risk of borderline prolonged QTc (>440 ms) and prolonged QTc (>460 ms) between 430 adult women AN patients and 123 healthy controls using 3 correction formulas. In a follow-up study, we estimated the risk of a primary end point (a composite of ventricular tachycardia, aborted cardiac arrest, and cardiac arrest) in AN patients compared with a population-based cohort derived from the Danish Civil Register. Results: Mean QTc for AN patients was 408 ms (Hodges), 402 ms (Fridericia), and 399 ms (Bazett). Hodges’ found a slightly increased mean QTc (6.8 ms, 95% confidence interval, 1.6–12.0; P =0.01) and percentage with QTc >440 ms in AN patients (relative risk, 3.7, 95% confidence interval, 1.4–10.3; P =0.01), not observed with Fridericia’s and Bazett’s formulas. There was no difference in the risk of QTc >460 ms between AN patients and healthy controls. During a median follow-up of 10.1 years, AN patients had an increased risk of the primary end point compared with the population-based cohort (hazard ratio, 10.4, 95% confidence interval, 2.6–41.6; P =0.001). However, absolute numbers were small with cumulative incidences of 0.5% and 0.07%, respectively, after 10 years. No events occurred in any AN patient with QTc >440 ms. All-cause mortality was also significantly increased in AN patients compared with the population-based cohort (hazard ratio, 11.2, 95% confidence interval, 5.1–24.5; P <0.001). Conclusions: Overall, there was no difference in mean QTc interval or risk of prolonged QTc between AN patients and healthy controls. However, AN patients had a notably increased all-cause mortality, as well as an increased risk of cardiac events, which was not related to the baseline QTc interval.

21 June 2022 in EP Europace
Verified
Journal Article
Closed access
PDF file
kirstine calloekirstine calloe
kirstine calloe
MGMichelle Geryk
Michelle Geryk
KFKristine Freude
Kristine Freude
JTJacqueline A Treat
Jacqueline A Treat
VVVictoria A Vold
Victoria A Vold
Jonathan CordeiroJonathan Cordeiro
Jonathan Cordeiro
Variants in SCN5A encoding Nav1.5 are associated with cardiac arrhythmias. We aimed to determine the mechanism by which c.638G>A in SCNA5 resulting in p.Gly213Asp (G213D) in Nav1.5 altered Na+ channel function and how flecainide corrected the defect in a family with multifocal ectopic Purkinje-related premature contractions (MEPPC)-like syndrome. Five patients carrying the G213D variant were treated with flecainide. Gating pore currents were evaluated in Xenopus laevis oocytes. The 638G>A SCN5A variant was introduced to human-induced pluripotent stem cell (hiPSC) by CRISPR–Cas9 gene editing and subsequently differentiated to cardiomyocytes (hiPSC-CM). Action potentials and sodium currents were measured in the absence and presence of flecainide. Ca2+ transients were measured by confocal microscopy. The five patients exhibited premature atrial and ventricular contractions which were suppressed by flecainide treatment. G213D induced gating pore current at potentials negative to −50 mV. Voltage-clamp analysis in hiPSC-CM revealed the activation threshold of INa was shifted in the hyperpolarizing direction resulting in a larger INa window current. The G213D hiPSC-CMs had faster beating rates compared with wild-type and frequently showed Ca2+ waves and alternans. Flecainide applied to G213D hiPSC-CMs decreased window current by shifting the steady-state inactivation curve and slowed the beating rate. The G213D variant in Nav1.5 induced gating pore currents and increased window current. The changes in INa resulted in a faster beating rate and Ca2+ transient dysfunction. Flecainide decreased window current and inhibited INa, which is likely responsible for the therapeutic effectiveness of flecainide in MEPPC patients carrying the G213D variant. Flecainide treatment reduces MEPPC symptoms in patients with the G213D variant in Nav1.5. G213D shifts Nav1.5 activation to more negative voltages and induces a gating pore current. hIPSC cardiomyocytes have depolarised resting membrane potential, rapid firing and alternans, which can be improved by flecainide. Flecainide decreased INa, which is likely responsible for the therapeutic effectiveness.

3 May 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JDJohnni Resdal Dyssekilde
Johnni Resdal Dyssekilde
TFTanja Charlotte Frederiksen
Tanja Charlotte Frederiksen
MCMorten Krogh Christiansen
Morten Krogh Christiansen
RSRikke Hasle Sørensen
Rikke Hasle Sørensen
LPLisbeth Nørum Pedersen
Lisbeth Nørum Pedersen
HJHenrik Kjærulf Jensen
Henrik Kjærulf Jensen
Background: The cause of atrioventricular block (AVB) remains unknown in approximately half of young patients with the diagnosis. Although variants in several genes associated with cardiac conduction diseases have been identified, the contribution of genetic variants in younger patients with AVB is unknown.Methods and Results: Using the Danish Pacemaker and Implantable Cardioverter Defibrillator (ICD) Registry, we identified all patients younger than 50 years receiving a pacemaker because of AVB in Denmark in the period from January 1, 1996 to December 31, 2015. From medical records, we identified patients with unknown cause of AVB at time of pacemaker implantation. These patients were invited to a genetic screening using a panel of 102 genes associated with inherited cardiac diseases. We identified 471 living patients with AVB of unknown cause, of whom 226 (48%) accepted participation. Median age at the time of pacemaker implantation was 39 years (interquartile range, 32–45 years), and 123 (54%) were men. We found pathogenic or likely pathogenic variants in genes associated with or possibly associated with AVB in 12 patients (5%). Most variants were found in theLMNAgene (n=5).LMNAvariant carriers all had a family history of either AVB and/or sudden cardiac death.Conclusions: In young patients with AVB of unknown cause, we found a possible genetic cause in 1 out of 20 participating patients. Variants in theLMNAgene were most common and associated with a family history of AVB and/or sudden cardiac death, suggesting that genetic testing should be a part of the diagnostic workup in these patients to stratify risk and screen family members.